Furthermore, no mOS difference was seen between ICI monotherapy and chemoimmunotherapy in the KRAS mutant NSCLC patients (mOS, 21.1 vs 20.0 months; P = .78), suggesting that the use of ICI monotherapy in the PD-L1 TPS ≥50% is an acceptable option in the KRAS mutant advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.